Evidence map›Paper›PMID 31530293›Full record

ArticleBJPsych open2019

Exploring patients' and carers' views about the clinical use of ketamine to inform policy and practical decisions: mixed-methods study.

Sagar Jilka, Claire Murray, Ania Wieczorek, Helena Griffiths, Til Wykes, Rupert McShane

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJPsych open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sagar JilkaPost-doctoral Research Associate and Patient and Public Involvement Coordinator, Institute of Psychiatry, Psychology & Neuroscience, King's College London; and South London and Maudsley NHS Foundation Trust, UK.ORCID https://orcid.org/0000-0003-1578-9350
Claire MurrayPatient and Public Involvement Manager, Oxford Health NHS Foundation Trust, Warneford Hospital, UK.
Ania WieczorekService User Research Assistant, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK.
Helena GriffithsService User Research Assistant, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK.
Til WykesProfessor of Clinical Psychology and Rehabilitation and Vice Dean Psychology and System Sciences, Institute of Psychology, Psychiatry & Neuroscience, King's College London; and Consultant Clinical Psychologist, South London and Maudsley NHS Foundation Trust, UK.
Rupert McShaneAssociate Professor, Department of Psychiatry, University of Oxford; and Consultant Psychiatrist, Oxford Health NHS Trust, Warneford Hospital, Oxford, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOnly one-third of patients with major depressive disorder achieve remission. One new and promising treatment, ketamine, may prove challenging to implement because of its abuse potential. Although clinicians' views have been sought, we need patients' views before large scale roll-out is considered.

aimsTo explore patients' and carers' views to inform policy and practical decisions about the clinical use of ketamine.

methodWe carried out a mixed-methods study using data from 44 participants in 21 focus groups in three sessions and an online survey with patients, carers and advocates during a consultation day. Focus groups explored participant's views about ketamine as a form of treatment and the best way for ketamine to be prescribed and monitored. The qualitative data were analysed by two patient-researchers using an exploratory framework analysis and was supplemented by a survey.

resultsThe ten themes generated were monitoring, information, effect on daily life, side-effects, recreational use, effectiveness, appropriate support, cost, stigma and therapy. Participants wanted better evidence on the safety of ketamine after long-term use and felt that monitoring was required. Collecting this information would provide evidence for ketamine's safe use and administration. There were, however, concerns about the misuse of this information. Practical issues of access were important: repeated travelling to clinics and a lack of sufficiently informed medical staff were key barriers.

conclusionsClinicians have some similar and some different views to those of patients, carers and advocates, which need to be considered in any future roll-out of ketamine. DECLARATION OF INTEREST: R.M. has had UK National Institute for Health Research grant funding to study ketamine, is participating in trials of esketamine, runs a clinic that provides ketamine treatment, and has consulted for Johnson & Johnson and Eleusis.

Indexed as

depressive disordersDrugs of dependence disorderspatientsqualitative researchservice users

Identifiers

PMID31530293
PMCPMC6669880

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.